Growth hormone for in vitro fertilization.

What It Covers

This meta-analysis looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).

The researchers searched the Cochrane Menstrual Disorders and Subfertility Groups trials register (June 2009), the Cochrane Central Register of Controlled Trials (Cochrane Library Issue 2, 2009), MEDLINE (1966 to June 2009), EMBASE (1988 to June 2009) and Biological Abstracts (1969 to June 2009).

Assessment of trial risk of bias and extraction of relevant data was performed independently by two reviewers.

Who the Included Studies Covered

PubMed tags the participants as women only.

All randomised controlled trials were included if they addressed the research question and provided outcome data for intervention and control participants.

What Was Measured

Assessment of trial risk of bias and extraction of relevant data was performed independently by two reviewers.

The subject headings attached to it are Chemotherapy, Adjuvant, Fertilization in Vitro, Growth Hormone-Releasing Hormone, Human Growth Hormone, Infertility, Female, Live Birth and Ovulation Induction.

What This Means in Plain Language

This is a meta-analysis of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (The Cochrane database of systematic reviews), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.